Company Announcement - MYND Life Sciences has approved the issuance of 4,000,001 common shares at 3.5 million (CDN) debenture [1] - The issuance of shares for a total value of $2,840,000.71 has been completed, marking a significant inflection point for the company [2] - The details of the debenture settlement will be reflected in MYND's upcoming financial statements [3] Business Focus - MYND Life Sciences is a clinical-stage life sciences company focused on developing drug therapies and a proprietary biomarker test for Major Depressive Disorder (MDD) and Treatment-resistant Depression (TRD) [4] - The company's proprietary biomarker for depression aims to support personalized patient management strategies and offers near-term revenue opportunities [4] - MYND is developing the first test of its kind targeting depression, addressing a significant unmet need in the market [4]
MYND Life Sciences Announces the Issuance of 4,000,001 Shares at $0.71/share